GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes
Authors:
- 17 February 2026
- journal article
- review article
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (2) , 102494
Abstract
No abstract availableKeywords
This publication has 118 references indexed in Scilit:
- SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2Cellular and Molecular Life Sciences, 2025
- Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group TechniqueDiabetes Therapy, 2025
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristicsObesity, 2022
- “Vascular inflammation and cardiovascular disease: review about the role of PET imaging”The International Journal of Cardiovascular Imaging, 2022
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 DiabetesDiabetes Therapy, 2019
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney diseaseDiabetologia, 2019
- Impact of cardiovascular risk factors on vessel wall inflammation and calcified plaque burden differs across vascular beds: a PET-CT studyThe International Journal of Cardiovascular Imaging, 2013
- Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: What Leonardo da Vinci could not seeJournal of Nuclear Cardiology, 2012